Le Matin – Setback for AstraZeneca in the development of an anti-Covid treatment

  • Vaccine against the newcoronavirus
The Anglo-Swedish pharmaceutical group AstraZeneca announced on Tuesday that it had suffered a setback in the development of a treatment against the coronavirus, the effectiveness of which on people exposed to the virus has not been proven. This is an antibody treatment, the code name of which is AZD7442 and which should both prevent and treat the disease.

“The trial did not achieve the main goal of preventing symptomatic Covid-19 cases after exposure” to the virus, AstraZeneca explains in a statement. The treatment was in phase 3 of development, that is to say in large-scale clinical trials in order to measure its safety and effectiveness. The 1,121 participants were adults over the age of 18 who were not vaccinated and who had been exposed to an infected person during the previous eight days. The treatment only reduced the risk of developing Covid-19 with symptoms by 33%.

Trials are continuing to evaluate the remedy in patients before exposure to the virus, and for those who have developed severe forms. The development of this treatment is funded by the US government, which in turn had signed agreements with AstraZeneca to receive up to 700,000 doses this year. In total, the value of the agreements with the United States for the development of the treatment and the doses in 2021 reaches 726 million dollars.

In its press release, AstraZeneca indicates that discussions are underway “regarding the next steps with the US government”.

AstraZeneca is also still facing questions about its vaccine against Covid-19, suspended by several European countries after rare blood problems in vaccinated people. A senior official at the European Medicines Agency (EMA) even went so far as to estimate that it would be better to stop AstraZeneca’s vaccine against Covid-19 for all age groups when alternatives are available. .

At the same time, a study published on Monday by British health authorities found that two doses of the Pfizer / BioNTech or AstraZeneca / Oxford vaccines protect more than 90% against hospitalizations after contracting the Delta variant of the coronavirus, which initially appeared in India. .

Source: new.in-24.com

“The trial did not achieve the main goal of preventing symptomatic Covid-19 cases after exposure” to the virus, AstraZeneca explains in a statement. The treatment was in phase 3 of development, that is to say in large-scale clinical trials in order to measure its safety and effectiveness. The 1,121 participants were adults over the age of 18 who were not vaccinated and who had been exposed to an infected person during the previous eight days. The treatment only reduced the risk of developing Covid-19 with symptoms by 33%.

Trials are continuing to evaluate the remedy in patients before exposure to the virus, and for those who have developed severe forms. The development of this treatment is funded by the US government, which in turn had signed agreements with AstraZeneca to receive up to 700,000 doses this year. In total, the value of the agreements with the United States for the development of the treatment and the doses in 2021 reaches 726 million dollars.

In its press release, AstraZeneca indicates that discussions are underway “regarding the next steps with the US government”.

AstraZeneca is also still facing questions about its vaccine against Covid-19, suspended by several European countries after rare blood problems in vaccinated people. A senior official at the European Medicines Agency (EMA) even went so far as to estimate that it would be better to stop AstraZeneca’s vaccine against Covid-19 for all age groups when alternatives are available. .

At the same time, a study published on Monday by British health authorities found that two doses of the Pfizer / BioNTech or AstraZeneca / Oxford vaccines protect more than 90% against hospitalizations after contracting the Delta variant of the coronavirus, which initially appeared in India. .

Source: new.in-24.com